The complex airway multidisciplinary team later offered switching to an anti-IL-5 monoclonal antibody (mepolizumab) for continued CRSwNP control, but the patient declined further monoclonal therapy. Here, IL5 is linked to chronic rhinosinusitis with nasal polyps.